Sanofi, Doud­na-found­ed Scribe Ther­a­peu­tics to tar­get sick­le cell dis­ease in new pact

Sanofi has inked an­oth­er col­lab­o­ra­tion with its CRISPR part­ner Scribe Ther­a­peu­tics as the duo seeks to cre­ate a new­er, safer ap­proach to tack­ling sick­le cell dis­ease.

The French phar­ma gi­ant will pay Scribe $40 mil­lion up­front, and it could dish out more than $1.2 bil­lion down the road for mile­stones across an undis­closed num­ber of pro­grams that will com­bine Scribe’s so-called CRISPR X-edit­ing tech and Sanofi’s non-vi­ral de­liv­ery tech­nolo­gies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER